(Q37721403)

22 August 2017

1 reference

title

Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections (English)

1 reference

22 August 2017

main subject

Clostridium difficile

0 references

antibiotic

0 references

author name string

Ian R Poxton

series ordinal

1

1 reference

22 August 2017

publication date

1 April 2010

1 reference

22 August 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

22 August 2017

volume

5

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

539-548

1 reference

Historical perspectives on studies of Clostridium difficile and C. difficile infection

22 August 2017

cites work

1 reference

Narrative review: the new epidemic of Clostridium difficile-associated enteric disease

21 January 2018

1 reference

Historical and changing epidemiology of healthcare-associated infections

21 January 2018

1 reference

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality

21 January 2018

1 reference

A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use.

21 January 2018

1 reference

Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain

21 January 2018

1 reference

A European survey of diagnostic methods and testing protocols for Clostridium difficile

21 January 2018

1 reference

Changes in laboratory and clinical workload for Clostridium difficile infection from 2003 to 2007 in hospitals in Edinburgh

21 January 2018

1 reference

Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005

21 January 2018

1 reference

Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study

21 January 2018

1 reference

Clostridium difficile associated infection, diarrhea and colitis

21 January 2018

1 reference

Recurrent Clostridium difficile infection: causality and therapeutic approaches

21 January 2018

1 reference

European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI).

21 January 2018

1 reference

Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study

21 January 2018

1 reference

Clostridium difficile: controversies and approaches to management.

21 January 2018

1 reference

Skin and environmental contamination with vancomycin-resistant Enterococci in patients receiving oral metronidazole or oral vancomycin treatment for Clostridium difficile-associated disease

21 January 2018

1 reference

Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial

21 January 2018

1 reference

Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review

21 January 2018

1 reference

The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy

21 January 2018

1 reference

Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series

21 January 2018

1 reference

New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration

21 January 2018

1 reference

In vitro activities of OPT-80 and comparator drugs against intestinal bacteria

21 January 2018

1 reference

Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species

21 January 2018

1 reference

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

21 January 2018

1 reference

Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses

21 January 2018

1 reference

Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection

21 January 2018

1 reference

Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FMB.10.20

1 reference

22 August 2017

1 reference